Lifitegrast

Lifitegrast
Clinical data
Trade names	Xiidra
Other names	SAR-1118
AHFS/Drugs.com	Monograph
MedlinePlus	a616039
Pregnancy; category	AU: B1;
Routes of; administration	Eye drops
ATC code	S01XA25 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name N-{[2-(1-Benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl}-3-(methylsulfonyl)-L-phenylalanine;
CAS Number	1025967-78-5;
PubChem CID	11965427;
DrugBank	DB11611;
ChemSpider	10139520;
UNII	038E5L962W;
KEGG	D10374;
ChEBI	CHEBI:133023 ;
ChEMBL	ChEMBL2048028;
CompTox Dashboard (EPA)	DTXSID60145345 ;
ECHA InfoCard	100.245.695
Chemical and physical data
Formula	C29H24Cl2N2O7S
Molar mass	615.48 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CS(=O)(=O)c1cccc(c1)C[C@@H](C(=O)O)NC(=O)c2c(cc3c(c2Cl)CCN(C3)C(=O)c4ccc5ccoc5c4)Cl;
	InChI InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1; Key:JFOZKMSJYSPYLN-QHCPKHFHSA-N;

Lifitegrast, sold under the brand name Xiidra (/ˈzaɪdrə/^[2]), is a medication for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca. Lifitegrast reduces inflammation by inhibiting inflammatory cell binding.^[3] It is often used as an alternative to ciclosporin (Ikervis, Restasis, Vevye, Verkazia or Cequa) for dry eye treatment including meibomian gland dysfunction and inflammatory dry eye.

^ "Eye health". Health Canada. 9 May 2018. Retrieved 13 April 2024.
^ "Patient information: Xiidra® (ZYE-druh) (lifitegrast ophthalmic solution) 5% for topical ophthalmic use" (PDF). Novartis. June 2020. Retrieved 5 February 2021.
^ Cite error: The named reference Tauber was invoked but never defined (see the help page).

[1] "Eye health". Health Canada. 9 May 2018. Retrieved 13 April 2024.

[2] "Patient information: Xiidra® (ZYE-druh) (lifitegrast ophthalmic solution) 5% for topical ophthalmic use" (PDF). Novartis. June 2020. Retrieved 5 February 2021.

[Tauber-3] Cite error: The named reference Tauber was invoked but never defined (see the help page).

[1]

[2]

[3]